{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:11:16Z","timestamp":1779189076081,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Verein zur Krebsforschung in der Frauenheilkunde"},{"name":"Verein zur Krebsforschung in der Frauenheildkunde"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46634-3","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:50:16Z","timestamp":1775033416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Absence of synergistic effects by CDK12\/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Fr\u00e9d\u00e9ric R.","family":"Santer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Hovdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Handle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Tsibulak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Wieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Ausserlechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walther","family":"Parson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Schnaiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain G.","family":"Zeimet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidelinde","family":"Fiegl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"46634_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA. Cancer J. Clin."},{"key":"46634_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/annonc\/mdx011","volume":"28","author":"A Karam","year":"2017","unstructured":"Karam, A. et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: First-line interventions. Ann. Oncol. 28, 711\u2013717 (2017).","journal-title":"Ann. Oncol."},{"key":"46634_CR3","first-page":"227","volume":"12","author":"I Vergote","year":"2020","unstructured":"Vergote, I. et al. Treatment algorithm in patients with ovarian cancer. Facts Views Vis. Obgyn. 12, 227\u2013239 (2020).","journal-title":"Facts Views Vis. Obgyn."},{"key":"46634_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl. J. Med."},{"key":"46634_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402 (2019).","journal-title":"N. Engl. J. Med."},{"key":"46634_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander, M. et al. Clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer 21, 771\u2013775 (2011).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"46634_CR7","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.3802\/jgo.2022.33.e44","volume":"33","author":"RE Miller","year":"2022","unstructured":"Miller, R. E., El-Shakankery, K. H. & Lee, J.-Y. PARP inhibitors in ovarian cancer: Overcoming resistance with combination strategies. J. Gynecol. Oncol. 33, e44 (2022).","journal-title":"J. Gynecol. Oncol."},{"key":"46634_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/21541264.2018.1535211","volume":"10","author":"AL Greenleaf","year":"2019","unstructured":"Greenleaf, A. L. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millennium. Transcription 10, 91\u2013110 (2019).","journal-title":"Transcription"},{"key":"46634_CR9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1634\/theoncologist.2019-0214","volume":"24","author":"ES Sokol","year":"2019","unstructured":"Sokol, E. S. et al. Pan-cancer analysis of CDK12 loss-of-function alterations and their association with the focal tandem-duplicator phenotype. Oncologist 24, 1526\u20131533 (2019).","journal-title":"Oncologist"},{"key":"46634_CR10","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1158\/0008-5472.CAN-15-2128","volume":"76","author":"T Popova","year":"2016","unstructured":"Popova, T. et al. Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications. Cancer Res. 76, 1882\u20131891 (2016).","journal-title":"Cancer Res."},{"key":"46634_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","volume":"74","author":"I Bajrami","year":"2014","unstructured":"Bajrami, I. et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity. Cancer Res. 74, 287\u2013297 (2014).","journal-title":"Cancer Res."},{"key":"46634_CR12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4161\/cc.11.6.19678","volume":"11","author":"D Blazek","year":"2012","unstructured":"Blazek, D. The cyclin K\/Cdk12 complex: An emerging new player in the maintenance of genome stability. Cell Cycle 11, 1049\u20131050 (2012).","journal-title":"Cell Cycle"},{"key":"46634_CR13","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1101\/gad.16962311","volume":"25","author":"D Blazek","year":"2011","unstructured":"Blazek, D. et al. The cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25, 2158\u20132172 (2011).","journal-title":"Genes Dev."},{"key":"46634_CR14","doi-asserted-by":"publisher","first-page":"9247","DOI":"10.1074\/jbc.M114.551143","volume":"289","author":"PM Joshi","year":"2014","unstructured":"Joshi, P. M., Sutor, S. L., Huntoon, C. J. & Karnitz, L. M. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J. Biol. Chem. 289, 9247\u20139253 (2014).","journal-title":"J. Biol. Chem."},{"key":"46634_CR15","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1093\/nar\/gkv101","volume":"43","author":"KM Ekumi","year":"2015","unstructured":"Ekumi, K. M. et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12\/CycK complex. Nucleic Acids Res. 43, 2575\u20132589 (2015).","journal-title":"Nucleic Acids Res."},{"key":"46634_CR16","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/s41467-019-09703-y","volume":"10","author":"M Krajewska","year":"2019","unstructured":"Krajewska, M. et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat. Commun. 10, 1757 (2019).","journal-title":"Nat. Commun."},{"key":"46634_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","volume":"564","author":"SJ Dubbury","year":"2018","unstructured":"Dubbury, S. J., Boutz, P. L. & Sharp, P. A. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature 564, 141\u2013145 (2018).","journal-title":"Nature"},{"key":"46634_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda, V. et al. Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer. Cancer Cell 36, 545-558.e7 (2019).","journal-title":"Cancer Cell"},{"key":"46634_CR19","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","volume":"17","author":"SF Johnson","year":"2016","unstructured":"Johnson, S. F. et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 17, 2367\u20132381 (2016).","journal-title":"Cell Rep."},{"key":"46634_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/gutjnl-2019-318506","volume":"69","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut 69, 727\u2013736 (2020).","journal-title":"Gut"},{"key":"46634_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ccell.2017.12.009","volume":"33","author":"AB Iniguez","year":"2018","unstructured":"Iniguez, A. B. et al. EWS\/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. Cancer Cell 33, 202-216.e6 (2018).","journal-title":"Cancer Cell"},{"key":"46634_CR22","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1158\/0008-5472.CAN-22-0222","volume":"82","author":"L Cheng","year":"2022","unstructured":"Cheng, L. et al. Dual inhibition of CDK12\/CDK13 targets both tumor and immune cells in ovarian cancer. Cancer Res. 82, 3588\u20133602 (2022).","journal-title":"Cancer Res."},{"key":"46634_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41420-023-01754-x","volume":"9","author":"T Houles","year":"2023","unstructured":"Houles, T. et al. The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma. Cell Death Discov. 9, 459 (2023).","journal-title":"Cell Death Discov."},{"key":"46634_CR24","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0124","author":"N Rajan","year":"2025","unstructured":"Rajan, N. et al. Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells. Endocr Relat Cancer https:\/\/doi.org\/10.1530\/ERC-24-0124 (2025).","journal-title":"Endocr Relat Cancer"},{"key":"46634_CR25","unstructured":"CDK12 DepMap Gene Summary. https:\/\/depmap.org\/portal\/gene\/CDK12?tab=characterization&characterization=expression."},{"key":"46634_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C. & Vazquez, F. The present and future of the Cancer Dependency Map. Nat Rev Cancer 25, 59\u201373 (2025).","journal-title":"Nat Rev Cancer"},{"key":"46634_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585\u2013615 (1939).","journal-title":"Ann. Appl. Biol."},{"key":"46634_CR28","doi-asserted-by":"publisher","first-page":"102948","DOI":"10.1016\/j.sbi.2024.102948","volume":"89","author":"M Davies","year":"2024","unstructured":"Davies, M., Boyce, M. & Conway, E. Short circuit: Transcription factor addiction as a growing vulnerability in cancer. Curr. Opin. Struct. Biol. 89, 102948 (2024).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"46634_CR29","doi-asserted-by":"publisher","first-page":"lqaf113","DOI":"10.1093\/nargab\/lqaf113","volume":"7","author":"JM Santos-Pereira","year":"2025","unstructured":"Santos-Pereira, J. M., Carnero, A. & Mu\u00f1oz-Galv\u00e1n, S. Integrative multi-omic analysis reveals a PAX8-driven gene network linking tumor stemness to therapy response in ovarian cancer. NAR Genom. Bioinform. 7, lqaf113 (2025).","journal-title":"NAR Genom. Bioinform."},{"key":"46634_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-023-02682-5","volume":"42","author":"E Cesari","year":"2023","unstructured":"Cesari, E. et al. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids. J. Exp. Clin. Cancer Res. 42, 126 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"46634_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J. Clin. Oncol. 33, 244\u2013250 (2015).","journal-title":"J. Clin. Oncol."},{"key":"46634_CR32","doi-asserted-by":"publisher","first-page":"109394","DOI":"10.1016\/j.celrep.2021.109394","volume":"36","author":"SM Dieter","year":"2021","unstructured":"Dieter, S. M. et al. Degradation of CCNK\/CDK12 is a druggable vulnerability of colorectal cancer. Cell Rep. 36, 109394 (2021).","journal-title":"Cell Rep."},{"key":"46634_CR33","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1096\/fj.04-3062fje","volume":"19","author":"W Parson","year":"2005","unstructured":"Parson, W. et al. Cancer cell line identification by short tandem repeat profiling: Power and limitations. FASEB J. 19, 434\u2013436 (2005).","journal-title":"FASEB J."},{"key":"46634_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ygyno.2022.01.008","volume":"165","author":"H Fiegl","year":"2022","unstructured":"Fiegl, H. et al. Dubious effects of methadone as an \u2018anticancer\u2019 drug on ovarian cancer cell-lines and patient-derived tumor-spheroids. Gynecol. Oncol. 165, 129\u2013136 (2022).","journal-title":"Gynecol. Oncol."},{"key":"46634_CR35","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli, G. Y. et al. Combenefit: An interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32, 2866\u20132868 (2016).","journal-title":"Bioinformatics"},{"key":"46634_CR36","doi-asserted-by":"publisher","first-page":"e1006752","DOI":"10.1371\/journal.pcbi.1006752","volume":"15","author":"A Malyutina","year":"2019","unstructured":"Malyutina, A. et al. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Comput. Biol. 15, e1006752 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"46634_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","volume":"139","author":"I Nicoletti","year":"1991","unstructured":"Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F. & Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139, 271\u2013279 (1991).","journal-title":"J. Immunol. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46634-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:02:11Z","timestamp":1779188531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46634-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46634"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46634-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15362"}}